Aditxt, Inc.

$0.0031 USD

$0.0 (-3.43%)

Volume: 2.92M
Average Volume: 418.15M
Market Capitalization: $3.09M
P/E Ratio: 0.00
Dividend Yield: 0.00%
Price Target: $1280.00

Year High: $31974.48
Year Low: $0.00
Day High: —
Day Low: —
Payout Ratio: $0.00
Current Ratio: $0.06

Industry, Sector & symbol

Stock Exchange	PNK
CEO	Jeffrey Busch
Industry	Biotechnology
Sector	Healthcare
Current Symbol	ADTX
CUSIP	007025869
CIK	0001726711
Web	https://www.aditxt.com
Phone	650 870 1200
Currency	USD
Employees	26
Country	US

Liquidity

Debt-to-Equity Ratio	-0.13
Payout Ratio	0.00
Current Ratio	0.06
Quick Ratio	0.05
Cash Ratio	0.02

Sales & Book Value

Annual Sales	$3195
Price / Sales	215.80
Cash Flow	-920.88
Price / Cash Flow	-0.17
Price / Book	0.00

Price Target and Rating

Average Stock Price Forecast	$1280.00
High Stock Price Forecast	$1280.00
Low Stock Price Forecast	$1280.00
Forecast Upside/Downside	-100.00%
Consensus Rating	Sell
Rating Score(0-5)	2
Research Coverage	2 Analysts

Profitability

EPS (Most Recent Fiscal Year)	-$1153.83
Trailing P/E Ratio	0.00
PEG Ratio	0.00
P/E Growth	0.00
Net Income	-$41.71M
Net Margin	-362385.72%
Pretax Margin	-369864.52%
Return on Equity	926.02%
Return on Assets	-373.57%

Financials Score

AltmanZ Score	-35.86
Piotroski Score	2.00
Working Capital	-12.49M
Total Assets	13.91M
Ebit	-50.94M
Market Cap	2.99M
Total Liabilities	49.08M

Poll Results

About Aditxt, Inc. (PNK:ADTX) Stock

Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues. Additionally, Aditxt is actively researching and developing ADi products with diverse therapeutic applications, such as for organ transplant procedures (including skin grafting), various autoimmune conditions, and allergic reactions. The company holds licensin ... g agreements with esteemed institutions like Loma Linda University and Leland Stanford Junior University. Established in 2017, this Richmond, Virginia-headquartered company was initially known as ADiTx Therapeutics, Inc. before rebranding to Aditxt, Inc. in July 2021.

Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million

2026-06-09 07:45:00

MOUNTAIN VIEW, Calif. & GOLDEN, Colo. & HONG KONG--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a qualified acquisition corp and Ignite Proteomics, LLC (“Ignite”, or “Ignite Proteomics”), a functional proteomics company and 100%-owned subsidiary of Aditxt, today announced that Ignite and strategic counterparty agreed to sign a definitive business combination agreement. The transaction values Ignite at an implied equity value of approximately $150 million, subject to the terms and co.

Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection

2026-06-08 08:15:00

GOLDEN, Colo.--(BUSINESS WIRE)--Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”) a subsidiary of Aditxt, Inc. (NASDAQ: ADTX), today announced the launch of a prospective oncology registry enrolling up to 10,000 patients. The registry is designed to pair Ignite's CLIA-certified Reverse Phase Protein Array (“RPPA”) platform with structured clinical outcomes tracking to evaluate the real-world utility of functional proteomics in cancer therapy selection. The initiative is expected to gener.

Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders

2026-06-01 08:15:00

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX)(“Aditxt” or the “Company”), a life sciences platform company accelerating promising health innovations, today announced the appointment of Jeffrey M. Busch as Interim Chief Executive Officer of Aditxt, Inc., effective May 31, 2026. Mr. Busch, who has served as Chief Executive Officer of Aditxt's CLIA-certified precision oncology diagnostics subsidiary Ignite Proteomics, LLC (“Ignite”) since March 2026, will now lead the full Ad.

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026

2026-05-14 08:15:00

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-27 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on May 18, 2026, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at the a.

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients

2026-04-20 08:15:00

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced that its precision oncology subsidiary, Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”), has been featured in a peer-reviewed study published online ahead of print in npj Precision Oncology, a Nature journal. The study, led by investigators at Dana-Farber Cancer Institute, evaluated outcomes among patien.

Frequently Asked Questions

What is the current Aditxt, Inc. (ADTX) stock price?: Aditxt, Inc.(PNK:ADTX) stock price is $0.0031 in the last trading session. During the trading session, ADTX stock reached the peak price of $31974.48 while $0.002 was the lowest point it dropped to. The percentage change in ADTX stock occurred in the recent session was --3.43% while the dollar amount for the price change in ADTX stock was -$0.0.
ADTX's industry and sector of operation?: The PNK listed ADTX is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of ADTX?: Jeffrey Busch | Chief Executive Officer
Amro A. Albanna | Co-Founder, Chairman & Chief Executive Officer
Corinne D. Pankovcin | Chief Mergers & Acquisitions Officer
Thomas J. Farley | Chief Financial Officer
Shahrokh Shabahang | Co-Founder, Chief Innovation Officer & Secretary
How many employees does ADTX have?: Number of ADTX employees currently stands at 26. ADTX operates from 2569 Wyandotte Street, Mountain View, CA 94043, US.

Link for ADTX official website?: Official Website of ADTX is: https://www.aditxt.com
How do I contact ADTX?: ADTX could be contacted at phone #650 870 1200 and can also be accessed through its website. ADTX operates from 2569 Wyandotte Street, Mountain View, CA 94043, US.
How many shares of ADTX are traded daily?: The average number of ADTX shares traded daily for last 3 months was 418.15M.
What is the market cap of ADTX currently?: The market value of ADTX currently stands at $3.09M with its latest stock price at $0.0031